Opportunistic infections in non-human primates exposed to immunomodulatory biotherapeutics: Considerations and case examples

Journal of Immunotoxicology

Volumn 7, Issue 2, 2010, Pages 120-127

  Hutto, David L ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Biotherapeutics; Immunomodulation; Non human primates; Opportunistic infections

Indexed keywords

ALEFACEPT; EFALIZUMAB; IMMUNOMODULATING AGENT; NATALIZUMAB; RITUXIMAB; VIRUS FUSION PROTEIN;

B LYMPHOCYTE; BLOOD PARASITE; DRUG SAFETY; GAMMAHERPESVIRINAE; IMMUNOMODULATION; LYMPHADENOPATHY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE FUNCTION; NONHUMAN; OPPORTUNISTIC INFECTION; POLYOMAVIRUS INFECTION; PRIMATE DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; T LYMPHOCYTE; VIRUS ENCEPHALITIS;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GAMMAHERPESVIRINAE; HAPLORHINI; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MONKEY DISEASES; OPPORTUNISTIC INFECTIONS; PLASMODIUM; POLYOMAVIRUS; TOXICITY TESTS;

POLYOMAVIRUS; PRIMATES;

EID: 77952149815     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.3109/15476910903258252     Document Type: Review

References (22)

1. Alefacept Package Insert: http://www.fda.gov/cder/foi/label/2003/ alefbio013003LB.pdf.
2. Chadburn, A., Cesarman, E., and Knowles, D. M. 1997. Molecular pathology of post-transplantation lymphoproliferative disorders. Semin. Diagn. Pathol. 14:15-26.
3. Coatney, G. R., Collins, W. E., Warren, M., and Contacos, P. G. (Eds.) 2003. The Primate Malarias. Atlanta: Centers for Disease Control, Division of Parasitic Diseases.
4. Cooper, J. C., Morgan, G., Harding, S., Subramanyam, M., Majeau, G. R., Moulder, K., and Alexander, D. R. 2003. Alefacept selectively promotes NK cell-mediated deletion of CD45R0 human T-cells. Eur. J. Immunol. 33:666-675.
5. Da Silva, A. J., Brickelmaier, M., Majeau, G. R., Li, Z., Su, L., Hsu, Y. M., and Hochman, P. S. 2002. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16- dependent apoptosis of CD2+ cells. J. Immunol. 168:4462-4471.
6. Farman, C. A., and Kornburst, D. J. 2003. Oligodeoxynucleotide studies in primates: Anti-sense and immune stimulatory indications. Toxicol. Pathol. 31:119-122.
7. FDA Medwatch: http://www.fda.gov/medwatch/SAFETY/2008/Jan-PI/ Rituxan-jan24-PI.pdf; http://www.fda.gov/medwatch/safety/2006/ tysabri-DHCPL.pdf; and http://www.fda.gov/medwatch/safety/2008/ Raptiva-PI.pdf
8. Harris, N. L., Ferry, J. A., and Swerdlow, S. H. 1997. Post-transplant lymphoproliferative disorders: Summary of society for hematopathology workshop. Sem. Diagn. Pathol. 14:8-14.
9. Horvath, C. J., Simon, M. A., Bergsagel, D. J., Pauley, D. R., King, N. W., Garcea, R. L., and Ringler, D. J. 1992. Simian virus 40-induced disease in rhesus monkeys with simian acquired immunodeficiency syndrome. Am. J. Pathol. 140:1431-1440.
10. Knowles, D. M., Cesarman, E., Chadburn, A., Frizzera, G., Chen, J., Rose, E. A., and Michler, R. E. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. A Soci of Hema 85:552-565.
11. Kumar, V., Abbas, A. K., and Fausto, N. (Eds.) 2005. Robbins and Cotran: Pathologic Basis of Disease. 7th ed. Philadeliphia: Elsevier Saunders.
12. Mauel, J., and Behin, R. 1974. Cell-mediated and humoral immunity to protozoan infections. Immunol. Rev. 19:121-146.
13. McInnes, E. F., Jarrett, R. F., Langford, G., Atkinson, C., Horsley, J., Goddard, M. J., Cozzi, E., and Schuurman, H. J. 2002. Post-transplant lymphoproliferative disorder associated with primate gammaherpesvirus in cynomolgus monkeys used in pig-to-primate renal xenotransplantation and primate renal allotransplantation. Transplantation 73:44-52.
14. Mota, M. M., Brown, K. N., Holder, A. A., and Jarra, W. 1998. Acute Plasmodium chabaudi malaria infection induces antibodies that bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro. Infect. Immun 66:4080-4086.
15. Nalesnik, M. A., Jaffe, R., Starzl, T. E., Demetris, A. J., Porter, K., Burnham, J. A., Makowka, L., Ho, M., and Locker, J. 1988. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone. Am. J. Pathol. 133:173-192.
16. Ockenhouse, C. F., Schulman, S., and Shear, H. L. 1984. Induction of crisis forms in the human malaria parasite Plasmodium falciparum by ?-interferon-activated, monocyte-derived macrophages. J. Immunol. 133:1601-1608.
17. Paya, C. V., Fung, J. J., Nalesnik, M. A., Kieff, E., Green, M., Gores, G., Habermann, T. M., Wiesner, R. H.; Swinnen, L. J., Woodle, E. S., and Bromberg, J. S. 1999. Epstein-Barr Virus-induced post-transplant lymphoproliferative disorders. Transplantation 68:1517-1525.
18. Schmidtko, J., Wang, R., Wu, C. L., Mauiyyedi, S., Harris, N. L., Della-Pella, P., Brousaides, N., Zagachin, L., Ferry, J. A., Wang, F., Kawai, T., Sachs, D. H., Benedict, C. A., and Colvin, R. B. 2002. Post-transplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 73:1431-1439.
19. Simon, M. A., Ilyinskii, P. O., Baskin, G. B., Knight, H. Y., Pauley, D. R., and Lackner, A. A. 1999. Association of simian virus 40 with a central nervous system lesion distinct from progressive multifocal leukoencephalopathy in macaques with AIDS. Am. J. Pathol. 154:437-446.
20. Thomason, R. W., Craig, F. E., Banks, P. M., Sears, D. L., Myerson, G. E., and Gulley, M. L. 1996. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod. Pathol. 9:261-266.
21. Wachtman, L. M., and Mansfield, K. G. 2008. Opportunistic infections in immunologically-compromised non-human primates. ILAR J. 49:191-208.
22. Wozencraft, A. O., Dockrell, H. M., Taverne, J., Targett, G. A., and Playfair, J. H. 1984. Killing of human malaria parasites by macrophage secretory products. Infect. Immun. 43:664-669.